Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension

Roberto F. Machado, Sabrina Martyr, Gregory J. Kato, Robyn J. Barst, Anastasia Anthi, Michael R. Robinson, Lori Hunter, Wynona Coles, James Nichols, Christian Hunter, Vandana Sachdev, Oswaldo Castro, Mark T. Gladwin

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Pulmonary hypertension is a frequent complication of sickle cell disease that is associated with haemolysis, impaired nitric oxide bioavailability and high mortality. We sought to evaluate the safety and efficacy of selective pulmonary vasodilators and antiproliferative agents in this at-risk population. After optimising sickle cell disease therapy to stabilise haemoglobin and fetal haemoglobin levels, we evaluated the safety and efficacy of sildenafil in 12 patients with sickle cell disease and pulmonary hypertension. Sildenafil therapy (mean duration 6 ± 1 months) decreased the estimated pulmonary artery systolic pressure [50 ± 4 to 41 ± 3 mmHg; difference 9 mmHg, 95% confidence interval (CI): 0·3-17, P = 0·043] and increased the 6-min walk distance (384 ± 30 to 462 ± 28 m; difference 78 m, 95% CI: 40-117, P = 0·0012). Transient headaches occurred in two patients and transient eye-lid oedema in four patients. No episodes of priapism occurred in the three men in the study; two of them were on chronic exchange transfusions and one had erectile dysfunction. In conclusion: (1) sickle cell disease patients with anaemia and pulmonary hypertension have significant exercise limitation; (2) the 6-min walk distance may be a valid endpoint in this population; (3) therapy with sildenafil appears safe and improves pulmonary hypertension and exercise capacity. Additional phase I studies in males with sickle cell disease followed by phase II/III placebo controlled trials evaluating the safety and efficacy of sildenafil therapy in sickle cell disease patients with pulmonary hypertension are warranted.

Original languageEnglish (US)
Pages (from-to)445-453
Number of pages9
JournalBritish journal of haematology
Volume130
Issue number3
DOIs
StatePublished - Aug 1 2005

Fingerprint

Sickle Cell Anemia
Pulmonary Hypertension
Safety
Therapeutics
Confidence Intervals
Exercise
Priapism
Fetal Hemoglobin
Erectile Dysfunction
Cell- and Tissue-Based Therapy
Hemolysis
Vasodilator Agents
Pulmonary Artery
Biological Availability
Headache
Sildenafil Citrate
Anemia
Edema
Nitric Oxide
Hemoglobins

Keywords

  • 6-min walk test
  • Haemolysis
  • Nitric oxide
  • Phosphodiesterase 5 inhibitors
  • Pulmonary hypertension
  • Sickle cell disease

ASJC Scopus subject areas

  • Hematology

Cite this

Machado, R. F., Martyr, S., Kato, G. J., Barst, R. J., Anthi, A., Robinson, M. R., ... Gladwin, M. T. (2005). Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. British journal of haematology, 130(3), 445-453. https://doi.org/10.1111/j.1365-2141.2005.05625.x

Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. / Machado, Roberto F.; Martyr, Sabrina; Kato, Gregory J.; Barst, Robyn J.; Anthi, Anastasia; Robinson, Michael R.; Hunter, Lori; Coles, Wynona; Nichols, James; Hunter, Christian; Sachdev, Vandana; Castro, Oswaldo; Gladwin, Mark T.

In: British journal of haematology, Vol. 130, No. 3, 01.08.2005, p. 445-453.

Research output: Contribution to journalArticle

Machado, RF, Martyr, S, Kato, GJ, Barst, RJ, Anthi, A, Robinson, MR, Hunter, L, Coles, W, Nichols, J, Hunter, C, Sachdev, V, Castro, O & Gladwin, MT 2005, 'Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension', British journal of haematology, vol. 130, no. 3, pp. 445-453. https://doi.org/10.1111/j.1365-2141.2005.05625.x
Machado, Roberto F. ; Martyr, Sabrina ; Kato, Gregory J. ; Barst, Robyn J. ; Anthi, Anastasia ; Robinson, Michael R. ; Hunter, Lori ; Coles, Wynona ; Nichols, James ; Hunter, Christian ; Sachdev, Vandana ; Castro, Oswaldo ; Gladwin, Mark T. / Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. In: British journal of haematology. 2005 ; Vol. 130, No. 3. pp. 445-453.
@article{0f6cba6c2fee4cdcb7406938ea4a110f,
title = "Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension",
abstract = "Pulmonary hypertension is a frequent complication of sickle cell disease that is associated with haemolysis, impaired nitric oxide bioavailability and high mortality. We sought to evaluate the safety and efficacy of selective pulmonary vasodilators and antiproliferative agents in this at-risk population. After optimising sickle cell disease therapy to stabilise haemoglobin and fetal haemoglobin levels, we evaluated the safety and efficacy of sildenafil in 12 patients with sickle cell disease and pulmonary hypertension. Sildenafil therapy (mean duration 6 ± 1 months) decreased the estimated pulmonary artery systolic pressure [50 ± 4 to 41 ± 3 mmHg; difference 9 mmHg, 95{\%} confidence interval (CI): 0·3-17, P = 0·043] and increased the 6-min walk distance (384 ± 30 to 462 ± 28 m; difference 78 m, 95{\%} CI: 40-117, P = 0·0012). Transient headaches occurred in two patients and transient eye-lid oedema in four patients. No episodes of priapism occurred in the three men in the study; two of them were on chronic exchange transfusions and one had erectile dysfunction. In conclusion: (1) sickle cell disease patients with anaemia and pulmonary hypertension have significant exercise limitation; (2) the 6-min walk distance may be a valid endpoint in this population; (3) therapy with sildenafil appears safe and improves pulmonary hypertension and exercise capacity. Additional phase I studies in males with sickle cell disease followed by phase II/III placebo controlled trials evaluating the safety and efficacy of sildenafil therapy in sickle cell disease patients with pulmonary hypertension are warranted.",
keywords = "6-min walk test, Haemolysis, Nitric oxide, Phosphodiesterase 5 inhibitors, Pulmonary hypertension, Sickle cell disease",
author = "Machado, {Roberto F.} and Sabrina Martyr and Kato, {Gregory J.} and Barst, {Robyn J.} and Anastasia Anthi and Robinson, {Michael R.} and Lori Hunter and Wynona Coles and James Nichols and Christian Hunter and Vandana Sachdev and Oswaldo Castro and Gladwin, {Mark T.}",
year = "2005",
month = "8",
day = "1",
doi = "10.1111/j.1365-2141.2005.05625.x",
language = "English (US)",
volume = "130",
pages = "445--453",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension

AU - Machado, Roberto F.

AU - Martyr, Sabrina

AU - Kato, Gregory J.

AU - Barst, Robyn J.

AU - Anthi, Anastasia

AU - Robinson, Michael R.

AU - Hunter, Lori

AU - Coles, Wynona

AU - Nichols, James

AU - Hunter, Christian

AU - Sachdev, Vandana

AU - Castro, Oswaldo

AU - Gladwin, Mark T.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Pulmonary hypertension is a frequent complication of sickle cell disease that is associated with haemolysis, impaired nitric oxide bioavailability and high mortality. We sought to evaluate the safety and efficacy of selective pulmonary vasodilators and antiproliferative agents in this at-risk population. After optimising sickle cell disease therapy to stabilise haemoglobin and fetal haemoglobin levels, we evaluated the safety and efficacy of sildenafil in 12 patients with sickle cell disease and pulmonary hypertension. Sildenafil therapy (mean duration 6 ± 1 months) decreased the estimated pulmonary artery systolic pressure [50 ± 4 to 41 ± 3 mmHg; difference 9 mmHg, 95% confidence interval (CI): 0·3-17, P = 0·043] and increased the 6-min walk distance (384 ± 30 to 462 ± 28 m; difference 78 m, 95% CI: 40-117, P = 0·0012). Transient headaches occurred in two patients and transient eye-lid oedema in four patients. No episodes of priapism occurred in the three men in the study; two of them were on chronic exchange transfusions and one had erectile dysfunction. In conclusion: (1) sickle cell disease patients with anaemia and pulmonary hypertension have significant exercise limitation; (2) the 6-min walk distance may be a valid endpoint in this population; (3) therapy with sildenafil appears safe and improves pulmonary hypertension and exercise capacity. Additional phase I studies in males with sickle cell disease followed by phase II/III placebo controlled trials evaluating the safety and efficacy of sildenafil therapy in sickle cell disease patients with pulmonary hypertension are warranted.

AB - Pulmonary hypertension is a frequent complication of sickle cell disease that is associated with haemolysis, impaired nitric oxide bioavailability and high mortality. We sought to evaluate the safety and efficacy of selective pulmonary vasodilators and antiproliferative agents in this at-risk population. After optimising sickle cell disease therapy to stabilise haemoglobin and fetal haemoglobin levels, we evaluated the safety and efficacy of sildenafil in 12 patients with sickle cell disease and pulmonary hypertension. Sildenafil therapy (mean duration 6 ± 1 months) decreased the estimated pulmonary artery systolic pressure [50 ± 4 to 41 ± 3 mmHg; difference 9 mmHg, 95% confidence interval (CI): 0·3-17, P = 0·043] and increased the 6-min walk distance (384 ± 30 to 462 ± 28 m; difference 78 m, 95% CI: 40-117, P = 0·0012). Transient headaches occurred in two patients and transient eye-lid oedema in four patients. No episodes of priapism occurred in the three men in the study; two of them were on chronic exchange transfusions and one had erectile dysfunction. In conclusion: (1) sickle cell disease patients with anaemia and pulmonary hypertension have significant exercise limitation; (2) the 6-min walk distance may be a valid endpoint in this population; (3) therapy with sildenafil appears safe and improves pulmonary hypertension and exercise capacity. Additional phase I studies in males with sickle cell disease followed by phase II/III placebo controlled trials evaluating the safety and efficacy of sildenafil therapy in sickle cell disease patients with pulmonary hypertension are warranted.

KW - 6-min walk test

KW - Haemolysis

KW - Nitric oxide

KW - Phosphodiesterase 5 inhibitors

KW - Pulmonary hypertension

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=24944476691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944476691&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05625.x

DO - 10.1111/j.1365-2141.2005.05625.x

M3 - Article

C2 - 16042696

AN - SCOPUS:24944476691

VL - 130

SP - 445

EP - 453

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -